PacBio Looks to Raise up to $200M in IPO; Reports $15M Order Backlog

The company disclosed in the filing that it has generated revenue of $1.2 million — all from government grants — for the first six months of 2010. As of June 30, it had a backlog of "firm" orders of approximately $15 million, and as of mid-August, it had shipped five early-access PacBio RS instruments.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.